12–18 October 2026
What moved in longevity science this week, what it changes for what gets built, funded, approved and priced, and what is being sold far ahead of its evidence. Global signal, India lens.
This week in 30 seconds
| Not yet | A blood aging score is now being used to set GLP-1 treatment plans. Builders of clock-based services have a working template. No regulatory action on Accrua has been reported, and whether such a score counts as a clinical claim is untested. |
| Yes | A non-dopaminergic Parkinson's adjunct met its Phase 3 primary by 37 minutes a day. Cerevance has a filing-grade adjunct outside dopamine replacement and payers a pricing question; if the difference survives peer review, the average patient loses 37 minutes of daily OFF time. |
| Contested | Has senolytics actually weakened, or did it just get a randomised win we never carried? Two readings, and the only randomised trial is 31 patients with 82% adverse events. |
Changes what gets built, funded, approved or priced: 1 yes · 1 not yet · 0 no
What this issue rests on · 22 sources
| ON THE LADDER |
| Lab and animals · 3 |
| People, watched · 3 |
| People, tested on a stand-in · 6 |
| People, tested on what matters · 1 |
| BESIDE IT |
| Measurement and methods · 1 |
| Not a study · 8 |
◆◆◆◇◇ Every study sits on a five-step ladder, from lab to a person’s actual outcome. How to read it
Not a study
A blood aging score is now being used to set GLP-1 treatment plans
Does this change what gets built, funded, approved or priced?
Not yetBuilders of clock-based services have a working template. No regulatory action on Accrua has been reported, and whether such a score counts as a clinical claim is untested.
| Who | Deep Longevity (launch); separately Rubedo and an unnamed cream brand, no relationship reported |
|---|---|
| What | Telehealth launch, plus two company biomarker claims |
| How much | Quarterly retesting; 11 paired skin samples at Rubedo |
| Evidence | Stage not assignable: a launch has no study design; supporting readings are company-reported biomarkers |
| Product, price | Accrua GLP-1 treatment plans; no price announced |
| 2.1 years lower across 11 paired samples, p=0.032skin epigenetic age |
◆ Biomarkers are not outcomesA surrogate with no intervention-response validation is sold as a treatment-management tool.
Deep Longevity launched Accrua, a US telehealth service setting GLP-1 treatment plans against a blood-based aging score, retested quarterly. The score now sits inside a prescribing decision.
Rubedo reported skin epigenetic age 2.1 years lower across 11 paired photoaged samples, p=0.032, company-reported and unpublished. An unnamed cream claims two years off a marker, no sample size.
Genetic evidence pointed the other way on one outcome. A two-sample Mendelian randomisation across six ageing measures (People, watched) found short telomeres raised fibrotic lung disease risk, while epigenetic and proteomic age acceleration did not. That is one disease, not a verdict on clocks as a class. Two mouse reports tie clock readings to tissue state, but record no design, so both are stage not assignable. 1–6
HARMSNeither Deep Longevity nor Rubedo reports adverse events; the nearer risk is a drug plan set by an unvalidated reading.
WHAT WOULD MOVE THISA trial where clock-guided GLP-1 dosing beats standard dosing on a clinical outcome.
1 Longevity.Technology · Not a study · 2 Longevity.Technology · Phase Ib, open-label, topical senotherapeutic in atopic dermatitis patients, skin epigenetic-age biomarker endpoint · n = 11 · 3 early-stage single-arm trial · 4 two-sample Mendelian randomisation with pleiotropy dissection and replication · 5 bioRxiv · transcriptomic-aging-clock analysis across mouse intestinal and liver regeneration models · 6 animal intervention study (heterochronic ovary transplantation and parabiosis) with transcriptomic/epigenetic aging clock development
◆◆◆◆◆ People, tested on what matters
A non-dopaminergic Parkinson's adjunct met its Phase 3 primary by 37 minutes a day
Does this change what gets built, funded, approved or priced?
YesCerevance has a filing-grade adjunct outside dopamine replacement and payers a pricing question; if the difference survives peer review, the average patient loses 37 minutes of daily OFF time.
| Who | Cerevance |
|---|---|
| What | Phase 3 topline result |
| How much | 341 patients, 12 weeks |
| Evidence | People, tested on what matters. Randomised, double-blind, placebo-controlled Phase 3, company topline, not peer-reviewed |
| Product, price | Solengepras 150 mg once daily, adjunctive; no price announced |
| 0.61 hours less per day, p=0.0350OFF time versus placebo | 341 patients, 12 weeksrandomised |
◆ Funding is not validationThe result is a company topline; the full dataset is unpublished.
Cerevance reported that once-daily solengepras 150 mg, added to existing therapy, cut daily OFF time by 0.61 hours more than placebo at week 12 (12246, People, tested on what matters). The trial was randomised, double-blind and placebo-controlled, 341 patients, p=0.0350. OFF time is when symptoms return between doses, so the endpoint is what a patient feels.
Non-dopaminergic action is the commercial point: a win widens Parkinson's treatment beyond dopamine replacement. Thirty-seven minutes a day is modest at a clean p-value.
The data establish a 12-week symptom difference in one company-reported trial. Durability, disease modification and any advantage over optimising existing dopaminergic dosing are untested here. 7
HARMSInsomnia occurred in 6.2% of treated patients versus 0.9% on placebo, and dyskinesia in 4.4% versus 1.8%. Durability past 12 weeks is untested.
WHAT WOULD MOVE THISPeer-reviewed publication with longer follow-up showing the OFF-time gain holds against optimised dopaminergic dosing.
7 Longevity.Technology · Phase III, randomised, double-blind, placebo-controlled
Has senolytics actually weakened, or did it just get a randomised win we never carried?
| Reading A | Still weakening. This week's senolytic news is a company-reported skin biomarker and a preclinical completion promising clinical work in 2026. Neither reaches a patient-relevant endpoint. |
|---|---|
| Reading B | The call is out of date. A randomised dasatinib-plus-quercetin trial in MASH sat in our week-41 miss list, never carried. It reported fibrosis improvement in 47% versus 7% on placebo, MASH resolution 53% versus 7%, adverse events 82% versus 43%, called self-limiting, in 31 patients. Unpublished, so no stage is assignable, and 31 patients across those endpoints leave few events per cell. |
| What would settle it | Peer-reviewed publication of that MASH trial, plus replication large enough to weigh an 82% adverse-event rate. 2,8 |
Business signals
Regulation
- Three trials of a CHO-cell recombinant herpes zoster vaccine were registered; endpoints are zoster protection and safety, not cognition. 16
Money
- Genentech will pay Alector $100 million upfront and up to $1.17 billion in milestones for preclinical AL050 in Parkinson's. 9
- Tiny Health raised an oversubscribed $33 million Series B led by B Capital; adult testing volume now exceeds infant. 10
Pipeline
- Digbi Health reached all 50 US states via OpenLoop Health and MD Integrations: 300-plus employers, 700-plus prescribers. 11
- A disproportionality analysis flagged an audiovestibular adverse-event reporting pattern for GLP-1s, which cannot establish causation. 12
- Retatrutide and zenagamtide, neither approved, are sold online for unsupervised use with no clinical data. 13
- Arrowhead reported deep, durable tau reduction in healthy volunteers from ARO-MAPT, a Phase 1/2a interim analysis (People, tested on a stand-in). 14
- Monte Rosa's NEK7-targeting NLRP3 inhibitor moved several heart-risk inflammatory markers toward healthy levels in 108 people with obesity; company-reported. 15
India Watch
- India's prime minister launched IIT Madras's mission to map over 100 human brains at cellular resolution, plus a 1,000-section stroke atlas. 17
- FSSAI issued a notice to Dr Reddy's and Nestle Health Science over Celevida GLP+ muscle-preservation claims. 18
- A 1,200-person randomised mHealth lifestyle trial in Colombo (People, tested on a stand-in) reported 10-year risk scores, not events: the closest South Asian test available. 19
- AWGS 2025's BMI-adjusted muscle index flagged vulnerable patients the height-adjusted index missed, an argument for cohort-calibrated cut-offs. 20,21
Watching
| Trend | Activity / evidence | Where it stands |
|---|---|---|
| Epigenetic and proteomic age clocks, commercialisation | ↑ rising Measurement | Mortality association in cohorts; no clock shown treatment-responsive (see item). |
| Ovarian aging as a longevity target | ↑ rising◆◆◆◇◇ People, watched | Menopause datable as an abrupt multisystem shift; no intervention tested there. |
| GLP-1 expansion into healthspan medicine | ↑ rising◆◆◆◇◇ People, watched | Approved drugs, widening employer channels; new outcome evidence stays observational. |
| Inflammaging targets, IL-11 and cGAS-STING | ↑ rising◆◆◆◆◇ People, tested on a stand-in | NLRP3 biomarker data in 108 people with obesity, company-reported; lowering CRP remains untested. |
| Longevity clinics globalisation | ↑ rising Not a study | Cash-pay panels have no outcome validation; reimbursed geriatrics has pooled randomised care-organisation evidence. |
| Big pharma entry into aging indications | ↑ rising Not a study | Deal flow, not results: nine figures upfront for preclinical neurodegeneration. |
| Partial epigenetic reprogramming toward the clinic | ↑ rising◆◆◇◇◇ Animals | SRSF1 cut frailty progression 44%, median lifespan up 14%, 9-10 mice; maximum lifespan unreported. |
| Gut microbiome geroscience | ↑ rising Review | Adult testing volume and $33 million new capital, no decision-changing result. |
| GLP-1 muscle preservation combinations | → flat◆◆◇◇◇ Animals | Two more mouse targets, no human adjunct data; older men gain less lean mass. |
| Senolytics clinical translation | → flat◆◆◆◆◇ People, tested on a stand-in | Company biomarkers and preclinical milestones; status under revision against one small randomised trial. |
| Aging biomarker standardisation | → flat Measurement | Six competing frameworks in one week; no regulator accepts an aging surrogate. |
| India multiomics and genomics infrastructure | ↑ rising Not a study | National brain-atlas build-out launched; value depends on promised public access. |
Sources
Most longevity news is early. These plain guides cover what is already proven, stage by stage, with Indian sources first.
Scientist working at the intersection of computation, biology and medicine. Longevity, Interpreted. exists to understand the evidence, not sell an intervention.
All issues · Subscribe · Health by age · suchee.org · LinkedIn · Scholar